Adaptive Biotechnologies Corporation

33.1 USD -0.82 USD ( -2.42% )

Adaptive Biotechnologies Corporation (NYSE:ADPT)

Add ADPT to Watchlist


Business Profile
Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ research service and kit that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals; and T-Detect COVID for the confirmation of past COVID-19 infection. It also provides clonoSEQ diagnostic tests, which include immunosequencing services for use in the detection and monitoring of minimal residual disease in patients with select blood cancers; and immunoSEQ T-MAP COVID for vaccine developers and researchers to measure the T-cell immune response to vaccines. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer, autoimmune conditions, and infectious diseases. It serves the life sciences research, clinical diagnostics, and drug discovery customers. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. It also has a research collaboration with Curebase, Inc. to enhance patient participation in clinical studies. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington. [ Read More ]


United States of America



Market Cap

4.67B USD

Enterprise Value

4.09B USD

Dividend Yield


Buyback Yield


Intrinsic Valuation

ADPT Intrinsic Value
Intrinsic value based on company cash flows

The intrinsic value of one ADPT stock under the base scenario is 2.32 USD. Compared to the current market price of 33.1 USD, the company's shares are overvalued by 93%.

Analyst Rating

Analyst Price Target
ADPT Price Target

12 month price targets for ADPT stock made by Wall Street analysts. The average price target is 57.8 USD with a high forecast of 78.75 USD and a low forecast of 47.47 USD.

47.47 USD
Upside 43%
57.8 USD
Upside 75%
78.75 USD
Upside 138%


Competitors Valuation Chart
Adaptive Biotechnologies Corporation Competitors

Competitors Valuation Table
Adaptive Biotechnologies Corporation Competitors

Shareholder Return

Stock Performance
ADPT Price Statistics

ADPT Market
1 Week +4% +1%
6 Months -23% +8%
1 Year -33% +31%
3 Years -18% +65%

Stock Price
ADPT Price Chart


Forecasted Financials

Forecast of Future Revenue


Net Income
Forecast of Future Net Income


Adaptive Biotechnologies Corporation Revenue and Net Income forecasts made by Wall Street analysts.